Fennec Pharmaceuticals Stock Forecast, Price & News

Fennec Pharmaceuticals (NASDAQ:FENC) Frequently Asked Questions

Is Fennec Pharmaceuticals a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Fennec Pharmaceuticals stock.
View analyst ratings for Fennec Pharmaceuticals or view top-rated stocks.

How has Fennec Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Fennec Pharmaceuticals' stock was trading at $6.63 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, FENC shares have decreased by 33.2% and is now trading at $4.43.
View which stocks have been most impacted by COVID-19.

When is Fennec Pharmaceuticals' next earnings date?

Fennec Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 29th 2022.
View our earnings forecast for Fennec Pharmaceuticals.

How were Fennec Pharmaceuticals' earnings last quarter?

Fennec Pharmaceuticals Inc (NASDAQ:FENC) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.16) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.17) by $0.01.
View Fennec Pharmaceuticals' earnings history.

What price target have analysts set for FENC?

5 brokerages have issued 1-year price objectives for Fennec Pharmaceuticals' shares. Their forecasts range from $10.00 to $14.00. On average, they anticipate Fennec Pharmaceuticals' share price to reach $12.67 in the next year. This suggests a possible upside of 185.9% from the stock's current price.
View analysts' price targets for Fennec Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Fennec Pharmaceuticals' key executives?

Fennec Pharmaceuticals' management team includes the following people:

• Mr. Rostislav Raykov, Pres, CEO & Director (Age 42)
• Mr. Robert C. Andrade, Chief Financial Officer (Age 43)
• Mr. Mark Gowland, Controller
• Mr. Lei Fang, Pres of Pharstat Inc
• Ms. Anne McKay, Regulatory Consultant (Age 64)

Who are some of Fennec Pharmaceuticals' key competitors?

Some companies that are related to Fennec Pharmaceuticals include Poseida Therapeutics (PSTX), Molecular Partners (MOLN), SAB Biotherapeutics (SABS), Autolus Therapeutics (AUTL), Curis (CRIS), Cortexyme (CRTX), Passage Bio (PASG), Innate Pharma (IPHA), Cellectis (CLLS), CEL-SCI (CVM), Jounce Therapeutics (JNCE), MiNK Therapeutics (INKT), Innate Pharma (IPHYF), Lineage Cell Therapeutics (LCTX) and Ambrx Biopharma (AMAM).
View all of FENC's competitors.

What other stocks do shareholders of Fennec Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), VBI Vaccines (VBIV), Gilead Sciences (GILD), Trevena (TRVN), Aldeyra Therapeutics (ALDX), Coherus BioSciences (CHRS) and Exelixis (EXEL).

What is Fennec Pharmaceuticals' stock symbol?

Fennec Pharmaceuticals trades on the NASDAQ under the ticker symbol "FENC."

Who are Fennec Pharmaceuticals' major shareholders?

Fennec Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include DG Capital Management LLC (2.38%), Millennium Management LLC (0.99%), Harbert Fund Advisors Inc. (0.67%), BlackRock Inc. (0.22%), Morgan Stanley (0.16%) and Russell Investments Group Ltd. (0.12%).
View institutional ownership trends for Fennec Pharmaceuticals.

Which institutional investors are selling Fennec Pharmaceuticals stock?

FENC stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Russell Investments Group Ltd., BlackRock Inc., and Morgan Stanley.
View insider buying and selling activity for Fennec Pharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying Fennec Pharmaceuticals stock?

FENC stock was purchased by a variety of institutional investors in the last quarter, including Harbert Fund Advisors Inc., DG Capital Management LLC, Belvedere Trading LLC, Citadel Advisors LLC, Ancora Advisors LLC, and Geode Capital Management LLC.
View insider buying and selling activity for Fennec Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Fennec Pharmaceuticals?

Shares of FENC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fennec Pharmaceuticals' stock price today?

One share of FENC stock can currently be purchased for approximately $4.43.

How much money does Fennec Pharmaceuticals make?

Fennec Pharmaceuticals has a market capitalization of $115.22 million and generates $170 thousand in revenue each year. The company earns $-18.11 million in net income (profit) each year or ($0.62) on an earnings per share basis.

What is Fennec Pharmaceuticals' official website?

The official website for Fennec Pharmaceuticals is www.fennecpharma.com.

Where are Fennec Pharmaceuticals' headquarters?

Fennec Pharmaceuticals is headquartered at PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709.

How can I contact Fennec Pharmaceuticals?

Fennec Pharmaceuticals' mailing address is PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709. The company can be reached via phone at 919-636-4530 or via fax at 919-890-0490.